However, in fat tissues, its ability to induce fat breakdown surpasses that of the native glucose-dependent insulinotropic hormone (GIP)
Do not assume it lasts as long as brand-name products
Research applications of this combination include investigation of growth hormone physiology, dual receptor pharmacology, and the molecular mechanisms underlying synergistic growth hormone secretagogue activity
References Lillys selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight, 06 November 2025, Lilly, Briere DA, et al, Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept